Redhill BiopharmaSTU:2RH 18 PS Ratio is 6.62 as of Jul. 07, 2026, which is 44% below its 10-year median of 11.76. GuruFocus rates STU:2RH with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 951 Drug Manufacturers companies, Redhill Biopharma ranks better than 86.23% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Redhill Biopharma's share price is €8.2375.
Redhill Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €1.24. Hence, Redhill Biopharma's PS Ratio for today is 6.62.
Good Sign:
Redhill Biopharma Ltd stock PS Ratio (=8.68) is close to 1-year low of 8.24.
The historical rank and industry rank for Redhill Biopharma's PS Ratio or its related term are showing as below:
STU:2RH'
s PS Ratio Range Over the Past 10 Years
Min: 0.01 Med: 11.76 Max: 58862.27
Current: 0.56
During the past 13 years, Redhill Biopharma's highest PS Ratio was 58862.27. The lowest was 0.01. And the median was 11.76.
STU:2RH's PS Ratio is ranked better than 86.23% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs STU:2RH: 0.56
Redhill Biopharma Ltd revenue per share has been in decline over the past 3 years.
During the past 3 years, the average Revenue per Share Growth Rate was -95.50% per year.
During the past 13 years, Redhill Biopharma's highest 3-Year average Revenue per Share Growth Rate was 1000.10% per year. The lowest was -95.50% per year. And the median was 69.65% per year.
Back to Basics: PS Ratio
Redhill Biopharma (STU:2RH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Redhill Biopharma PS Ratio Related Terms
Redhill Biopharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Redhill Biopharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Redhill Biopharma PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Redhill Biopharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Redhill Biopharma's Share Price of today is €8.2375.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Redhill Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €1.24.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Redhill Biopharma (STU:2RH) has a PS Ratio of 6.62 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Redhill Biopharma and its competitors. This is 44% below median its historical median of 11.76. Over the past decade, Redhill Biopharma's PS Ratio has ranged from 0.01 to 58,862.27. According to the industry distribution chart, Redhill Biopharma ranks #131 out of 951 companies in the Drug Manufacturers industry, placing it in the top 13.8%.
Is Redhill Biopharma's PS Ratio too high?
Redhill Biopharma's current PS Ratio of 6.62 is 44% below median its 10-year median of 11.76. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 58,862.27. The Drug Manufacturers industry median PS Ratio is 2.28. Redhill Biopharma's value of 6.62 is 190.4% above this industry median. Based on the distribution chart, Redhill Biopharma ranks #131 out of 951 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Redhill Biopharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Redhill Biopharma's PS Ratio compare to SBFM and PRFX?
According to the Drug Manufacturers industry distribution chart, Redhill Biopharma ranks #131 out of 951 companies for PS Ratio. This places Redhill Biopharma in the top 14% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.28. Redhill Biopharma's value of 6.62 is 190.4% above this benchmark. Historically, Redhill Biopharma's own PS Ratio has ranged from 0.01 to 58,862.27 over the past decade. While the company's 10-year median is 11.76 vs. the industry median of 2.28, Redhill Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.28, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Redhill Biopharma's current PS Ratio of 6.62 is 190.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Redhill Biopharma and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redhill Biopharma's current PS Ratio is 6.62, which is 44% below median its own 10-year median of 11.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redhill Biopharma stock overvalued right now?
Redhill Biopharma (STU:2RH) has a current PS Ratio of 6.62. The current PS Ratio is 6.62, which is 44% below median its 10-year median of 11.76 and 190.4% above the Drug Manufacturers industry median of 2.28. Redhill Biopharma's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Redhill Biopharma (STU:2RH), the current PS Ratio is 6.62 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.
18GF Score
Get the complete analysis for STU:2RH
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RH has been successfully added to your 
